A 52-year-old woman with diabetes mellitus presents with persistent vulvovaginal candidiasis refractory to fluconazole therapy. Culture and susceptibility testing reveals Candida glabrata. Which feature distinguishes C. glabrata from C. albicans in terms of antifungal management?

## Candida glabrata vs. Candida albicans: Clinical Distinction ### The Critical Difference: Azole Resistance **High-Yield:** Candida glabrata is **germ tube-negative** and exhibits **reduced or variable susceptibility to azole antifungals** (fluconazole, itraconazole), requiring alternative agents like echinocandins or amphotericin B. This is the key clinical discriminator. ### Comparative Features Table | Feature | C. albicans | C. glabrata | | --- | --- | --- | | **Germ tube** | Positive | **Negative** | | **Pseudohyphae** | Present | Absent | | **Chlamydospores** | Present | Absent | | **Azole susceptibility** | Susceptible (usually) | **Reduced/resistant** | | **Morphology** | Yeast + filaments | Small yeast cells only | | **Echinocandin response** | Susceptible | Susceptible (preferred) | | **Clinical setting** | Mucosal, invasive | Vulvovaginitis, UTI, disseminated | ### Why This Case Matters **Key Point:** The patient's failure to respond to fluconazole is the clinical clue. C. glabrata causes treatment-refractory infections because it is intrinsically less susceptible to azoles than C. albicans. **Clinical Pearl:** C. glabrata is a small, yeast-only organism that lacks the filamentous forms (germ tubes, pseudohyphae) of C. albicans. Its resistance to azoles is often **dose-dependent** — high-dose fluconazole may work, but echinocandins (caspofungin, anidulafungin) are preferred for reliable cure. **Mnemonic:** **GLABRATA = No Germ tubes, Less Azole-susceptible, Requires Alternative therapy** ### Management Implications **Warning:** Do not assume all Candida species respond to fluconazole. Germ tube negativity should raise suspicion for C. glabrata or C. auris, both of which require antifungal susceptibility testing. **Tip:** In cases of recurrent or refractory vulvovaginal candidiasis, always request species identification and susceptibility testing. C. glabrata is increasingly common in such presentations. [cite:Candida glabrata epidemiology and resistance; Jawetz, Melnick & Adelberg's Medical Microbiology 28e Ch 44; Harrison 21e Ch 212]